New combo therapy targets rare abdominal cancer in early trial
NCT ID NCT03361436
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This early-phase trial tests the safety and best dose of the chemotherapy drug eribulin when given with radiation before surgery for a rare cancer called retroperitoneal liposarcoma. About 15 adults with this abdominal fat-cell tumor will receive the combination to see how well it shrinks the cancer before removal. The main goal is to find any serious side effects and determine if this approach is feasible for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.